P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.

Hemasphere · 2023 · PMC10429256

Europe PMC

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendp=0.1so close (0.05 < p ≤ 0.1)

MRD response after C2 showed a trend for longer mOS (NR vs. 19m, p=0.1; Figure 2A) and LFS (21.7m vs. 13.3m, p=0.1) with a similar trend for mOS performing a Mantel-Byar test at the same time-point.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.